A Phase I Study of Lenalidomide in Combination With Dexamethasone in Anti-MAG Demyelinating Sensorimotor Neuropathy
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Peripheral neuropathies
- Focus Adverse reactions
- 04 Aug 2023 Status changed from active, no longer recruiting to discontinued.
- 03 Nov 2021 Planned End Date changed from 30 Sep 2021 to 30 Dec 2023.
- 03 Nov 2021 Planned primary completion date changed from 30 Jun 2021 to 30 Jun 2022.